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Brief Clinical ReportsA case of interleukin-6–producing cardiac myxoma resembling
multicentric Castleman’s disease
Atsutomo Morishima, MD,* Akira Marui, MD, PhD,* Takeshi Shimamoto, MD, Yoshiaki Saji, MD,
Takeshi Nishina, MD, PhD, and Masashi Komeda, MD, PhD, Kyoto, JapanCardiac myxoma sometimes presents constitutive symptoms
such as fever and weight loss because of a production of
interleukin-6 (IL-6).1,2 Castleman’s disease (CD) presents
constitutional symptoms with lymphadenopathy, plasma
cell infiltration, polyclonal hypergammaglobulinemia, and
inflammatory reaction, which has been reported to be caused
by an overproduction of IL-6.3-5 Here, we report a rare case
of IL-6-producing cardiac myxoma resembling multicentric
CD with plasma cell infiltration.
CLINICAL SUMMARY
A 78-year-old man had weight loss, low-grade fever, and
advanced anemia for 6 months. After he was referred to our
hospital, gastrointestinal examination revealed no malignant
lesions. A chest x-ray film showed no pulmonary congestion
or cardiomegaly (cardiothoracic ratio ¼ 48%). Findings on
an electrocardiogram were not remarkable. Laboratory data
showed low white blood cell count, anemia, and a severe
inflammatory reaction (c-reactive reaction and erythrocyte
sedimentation rate; Figure 1). The laboratory data also
revealed polyclonal hypergammaglobulinemia and hypoal-
buminemia (Figure 1). We initially suspected myelodysplas-
tic syndrome because of the constitutive symptoms and
hematologic abnormalities; however, the chromosome
examination revealed no abnormality. On further examina-
tion, abnormal plasma cell infiltration, erythroid hypoplasia
in bone marrow (Figure 2), and a marked increase in plasma
IL-6 (26.2 pg/mL, normal 4 pg/mL) were observed, which
led to suspicion of multicentric CD with plasma cell infiltra-
tion. Thus, steroid and anti-IL-6 therapy was scheduled.
However, chest computed tomography revealed not only
mediastinal lymphadenopathy but also a large mass (40 3
30 mm) in the left atrium. Therefore, we suspected
IL-6-producing cardiac myxoma. The echocardiography
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40 mm, attached to intra-atrial septum in the left atrium.
The operation was performed under a standard cardiopul-
monary bypass with mild hypothermia. Through the right-
sided left atriotomy, a tumor was observed in the left atrium.
The tumor had a gelatin-like, smooth, and dark violet surface
with a diameter of 40 mm. Subsequently, the right atrium
was opened, and the tumor was completely resected from
the fossa ovalis. The resected lesion was directly closed.
Histologic examination showed the tumor to be cardiac
myxoma. Postoperative course was uneventful, and preoper-
ative abnormal laboratory data including IL-6 returned to the
normal range.
DISCUSSION
To our knowledge, this is the first report of an IL-6-pro-
ducing cardiac myxoma resembling multicentric CD with
plasma cell infiltration. In 1956, Castleman and colleagues
initially reported hyperplasia of mediastinal lymph node as
CD.3 CD has been classified into 3 histologic variants4,5:
(1) hyaline vascular variant, which accompanies hyalinized
vessels in the center of lymph follicles; (2) plasma cell var-
iant, which presents severe infiltration of plasma cell in the
lymph follicles; and (3) mixed variant, which is a combina-
tion of the 2 variants. CD is also clinically classified as uni-
centric and multicentric CD. The former presents a swelling
of 1 lymph node without systemic symptoms. The latter
presents swelling of multiple lymph nodes and constitutive
symptoms such as fever, weight loss, and fatigue. Patients
with multicentric CD show anemia, inflammation, poly-
clonal hypergammaglobulinemia, plasma cell infiltration,
and hypoalbuminemia.5
Although the exact incidence is unknown, CD is increas-
ingly relevant today due to its association with human im-
munodeficiency virus and human herpes virus-8.4 In
addition, the relationship between multicentric CD and the
elevation of IL-6 has been pointed out.3-5 IL-6 by itself
has paracrine, endocrine, and autocrine growth functions.1
IL-6 is a pleiotropic cytokine with a variety of biologic activ-
ities, including differentiation of B cell, thymocytes, and T
cells; activation of macrophages; and stimulation of hepato-
cytes to produce acute-phase proteins such as C-reactive
protein.
Recognition of the contribution of IL-6 overproduction to
the development of multicentric CD has led to attempts toCardiovascular Surgery c Volume 138, Number 2 499
Brief Clinical ReportsFIGURE 1. Laboratory data. Anemia, severe inflammation, polyclonal hypergammaglobulinemia, and hypoalbuminemia were observed. Interleukin-6
markedly increased. ESR, Erythrocyte sedimentation rate; A/G, albumin/globulin; Brackets, normal range.block IL-6 or its effects directly. The use of a humanized
monoclonal antibody to the human IL-6 receptor (tocilizu-
mab)6 has been studied in a series of 28 HIV-negative pa-
tients.7 Objective improvement was consistently noted in
lymphadenopathy and other physical findings, clinical
symptoms, and laboratory parameters. Of 15 patients in
the series on chronic steroids therapy for CD, 11 (73%)
were able to decrease or discontinue its use. Some patients
received treatment for up to 3 years, and side effects were
mostly mild infusion-related reactions and transient leuko-
penia. Long-term maintenance with tocilizumab may be
beneficial.8
The clinical presentation of cardiac myxoma is not spe-
cific and depends on their size, location, and mobility. Pa-
tients usually present with one or more of the triad of
intracardiac obstruction, embolism, and constitutional symp-
toms. Several studies have shown a relationship between
IL-6 plasma level and associated manifestations of cardiac
myxoma. Overproduction of IL-6 from cardiac myxoma in-500 The Journal of Thoracic and Cardiovascular Surduces constructional symptoms and inflammatory reactions
in both adults and children.9 The tumor size significantly
correlates with the preoperative IL-6 level, and IL-6 levels
normalize after the myxoma is excised.1,2,10 IL-6 may play
an important role in cardiac myxoma recurrence,11 whereas
‘‘familial myxoma’’ recurs without immunologic features,
inflammatory signs, or elevation of serum IL-6 levels.10
The level of IL-6 in the cerebrospinal fluid might be a good
marker for the neurologic manifestations of cardiac myx-
oma.12 In addition to IL-6, various cytokines and growth
factors, such as vascular endothelial growth factor, basic
fibroblast growth factor, and monocyte chemotactic pro-
tein-1, were involved in tumor growth and angiogenesis.13
Although cardiac myxoma usually presents as a benign neo-
plasm, these factors sometimes cause it to become malignant
(by recurrence, local invasion, and distant metastasis).
As shown in the present report, IL-6 from cardiac myx-
oma can induce several other conditions such as multiple
cerebellar hemorrhages,12 pseudovasculitis,14 mediastinalFIGURE 2. Abnormal plasma cell infiltration in bone marrow. A, Binuclear plasma cell. B, Poorly eccentric nuclear plasma cell. Peroxidase staining.gery c August 2009
Brief Clinical Reportslymphadenopathy,15 and left ventricular hypertrophy.16
However, there has been no report of cardiac myxoma
with plasma cell infiltration, which suggests CD. In the pres-
ent case, myelodysplastic syndrome was suspected because
of constitutional symptoms, low white blood cell count, and
severe anemia. However, chromosome examination denied
this diagnosis. Plasma cell infiltration and polyclonal hyper-
gammaglobulinemia with elevation of IL-6 strongly indi-
cated multicentric CD. It was fortunate that the cardiac
myxoma was detected just before steroid therapy was begun.
In summary, we experienced a rare case of cardiac myx-
oma resembling multicentric CD. Cardiac myxoma should
be ruled out even if there are poor cardiac symptoms in pa-
tients with constitutional symptoms accompanied by hema-
tologic and immunologic abnormalities.
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